Merck Aims To Be India’s Largest Vaccine Maker
This article was originally published in PharmAsia News
Merck says it expects to be the largest drug maker producing vaccines in India within five years. The firm's intent is to develop vaccines for treating cancer, diarrhea and shingles, three primary diseases in India. The government has a national immunization program that Merck seeks to be associated with in its vaccine production, but plans to associate with individual states as well. The head of MSD Pharma, Merck's India arm, said the firm also plans to launch its other drugs at a rate faster than the usual 17 to 20 years after launching in the United States or Europe, perhaps even simultaneously. (Click here for more
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.